Company Overview and News

to your dashboard

Headline News

3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock | InvestorPlace

2017-10-19 investorplace
During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. During this wrenching process, he has had to deal with litigation as well as the loss of a major shareholder, Bill Ackman. (164-0)

Buy More Shopify Inc (US) While It's Down | InvestorPlace

2017-10-19 investorplace
Is it time to shop-the-drop in Shopify Inc (US) (NYSE:SHOP)? If, like me, you demand a good deal but also worry about defective merchandise, then a bull call spread makes plenty of sense in SHOP stock. Let me explain. (187-1)

Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

2017-10-19 zacks
Chicago, IL – October 19, 2017 – Today, Zacks Equity Research discusses the Industry: Pharmaceuticals, Part 3, including Acorda Therapeutics (Nasdaq:(ACOR - Free Report)  – Free Report), BioMarin Pharmaceutical (Nasdaq:(BMRN - Free Report)  – Free Report), Valeant Pharmaceuticals International (NYSE:(VRX - Free Report)  – Free Report), Teva Pharmaceuticals (NYSE:(TEVA - Free Report)  – Free Report) and Sanofi (NYSE:(SNY - Free Report)  – Free Report). (257-0)

Pricing Pressure, Competition Remain Headwinds for Pharma Stocks

2017-10-18 zacks
While the drug pricing issue no longer remains a major headwind for pharma and biotech stocks, it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices. The sector, previously a Wall Street favorite, was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs. With the drug pricing controversy gaining steam since September 2015, companies like Valeant saw their share prices plunging as they found themselves in the midst of the controversy. (211-0)

ADP Chief Calls Ackman's Proxy Fight a Distraction From Plan - Bloomberg

2017-10-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (215-0)

Johnson & Johnson: Fully Priced As Operating Momentum Accelerates

2017-10-18 seekingalpha
I have long liked J&J for its responsible operations as well as discipline regarding leverage and M&A, which is paying off nowadays when some peers get burned. (360-0)

Allergan: This Pharma Darling Faces Uncertainty Too

2017-10-18 seekingalpha
Allergan has lost 40% of its value from the 2015 peak but remains a favourite for many investors. (369-0)

Pershing Square’s Nominees for ADP’s Transformation to Participate in a Fireside Chat | Business Wire

2017-10-17 businesswire
NEW YORK--(BUSINESS WIRE)--Pershing Square Capital Management, L.P. (“Pershing Square”) today announced that Pershing Square CEO Bill Ackman, Veronica Hagen and Paul Unruh (“The Nominees for ADP’s Transformation”) will participate in a fireside chat hosted and moderated by Sanford C. Bernstein & Co. (“Bernstein”) Senior Analyst Lisa Ellis in Chicago on October 19, 2017, at 1:00 PM EDT / 12:00 PM CDT to discuss ADP (NASDAQ: ADP). (288-0)

Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France

2017-10-16 marketwired
VANCOUVER, BC--(Marketwired - October 16, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on October 18-19, 2017. Cosmetic 360 is an international event that brings together the leading advancements in science with the largest, most influential cosmetics companies. (236-1)

Valeant: Will A Key Weakness Turn Into A Strength Moving Forward?

2017-10-16 seekingalpha
Valeant Pharmaceuticals International, Inc. (VRX) launched Siliq (brodalumab) in late July 2017 after the FDA approved the BLA (Biologics License Application) for the drug for subcutaneous use for patients with moderate-to-severe plaque psoriasis in February of the same year. With Valeant trying to stem the drop in sales of its dermatology business over the last year, the results of a new study might help give Siliq the edge it needs to seize market share and turn the business around, while shorts continue to grasp at straws amid real progress with the company. (231-3)

Valeant Reports Positive Results on Psoriasis Drug Siliq

2017-10-13 zacks
Valeant Pharmaceuticals International, Inc. (VRX - Free Report) announced that one of its divisions, Ortho Dermatologics, announced results from the long-term phase III extension study, AMAGINE-2. (321-5)

It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock

2017-10-13 investorplace
Back in 2015, Hillary Clinton sent out a tweet promising to tackle price gouging, and that about marked the end of a secular bull market for biotech stocks. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB), which had rallied from $65 in 2009 to nearly $400 in 2015, started to tumble, and many biotechs followed including Gilead Sciences, Inc. (NASDAQ:GILD). (189-1)

Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval

2017-10-13 seekingalpha
An FDA Ad Com recommended approval for ONCE’s gene therapy for biallelic RPE65-mediated inherited retinal disease. (693-2)

Shopify Inc (US) Stock News Is Dire, but So What?

2017-10-12 investorplace
Though the odds are good anyone reading this already knows it, on the off chance someone isn’t yet aware, shares of Shopify Inc (US) (NYSE:SHOP) are down nearly 20% since early October thanks to a so-called “bear attack” from a well-known short seller. That is, Citron Research has publicly called out the e-commerce company, labeling it a “get rich quick scheme” that would sooner or later draw scrutiny from the FTC and, valid or not, such Shopify stock news headlines are the last thing any owner of SHOP stock wants to see. (296-1)

Antacids Market Worth US $18.7 Billion by the End of 2025 Globally: Transparency Market Research

2017-10-12 prnewswire
"Considering the changing dietary habits and growing geriatric population worldwide, the global antacids market is anticipated to be on the rise in the upcoming years," explains a TMR analyst. As per statistics of the Asian Development Bank, the population of individuals above the age of 60 years in Asia is projected to touch 923 million by 2050. The elderly population that is more susceptible to gastroesophageal reflux diseases (GERD) and peptic ulcers is anticipated to account for significant demand for antacids in the region. (195-1)

Global Scar Treatment Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Type of Treatment by Type of Scars and by End User

2017-10-11 prnewswire
LONDON, Oct. 11, 2017 /PRNewswire/ -- Market Overview Scar treatment in the study refers to the treatment of marks on the skin surface, that appear when the skin is damaged. It includes various products and therapies performed by various dermatologists, cosmetologists and other skin specialists for fading away or completely removing the scars. Based on the type of scar, the global scar treatment market is segmented into topical, surface, laser, injectable and invasive surgical. (177-0)

New Strong Sell Stocks for October 11th

2017-10-11 zacks
Flowserve Corporation (FLS - Free Report) is a designer, manufacturer and distributor of industrial flow management equipment. The Zacks Consensus Estimate for its current year earnings has been revised 2.1% downward over the last 30 days. (269-2)

Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi

2017-10-10 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)

Ackman Says He Won't Compromise in Board Battle With ADP - Bloomberg

2017-10-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (247-1)

Shopify Stock Will Plunge Almost 50% Says Prominent Short-Seller

2017-10-07 investorplace
On Oct. 4, shares of Shopify Inc (US) (NYSE:SHOP) fell 11% after a bearish report was issued by Citron Research’s Andrew Left. On Thursday, shares are down even more and Shopify stock is down a whopping 20% in three days. (287-4)

A Thorough Review Of The Shopify Short Narrative - And Where It Fails

2017-10-06 seekingalpha
Spotlight Top Pick Shopify (SHOP) stock has fallen nearly 20% in two days on the heels of toxic accusations from a well-known short seller, Andrew Left of Citron research. Rather than summarize Citron Research's short thesis, here it is, straight from Left's mouth in a seven-minute video: (407-2)

Why Investor Bullishness About AT&T Inc. (T) Stock Should Scare You | InvestorPlace

2017-10-06 investorplace
The last time I wrote about AT&T Inc (NYSE:T) was mid-September. In that piece, I suggested the 5.2% yield of AT&T stock was hardly worth it. (180-1)

VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors

2017-10-06 prnewswire
BOSTON, Oct. 5, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE: VRX)  that it is investigating legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE: VRX). (165-0)

Valeant Pharmaceuticals (VRX) Stock Begs Just One Key Question

2017-10-05 investorplace
If you’re having a tough time handicapping Valeant Pharmaceuticals Intl Inc (NYSE:VRX), don’t beat yourself up. It is a moving target and VRX stock is a “gut feeling” kind of play in the midst of a major transition. Two more developments unveiled within the past few days further muddy the waters as to where Valeant — and VRX stock — may be going. (165-2)

How to Approach Valeant Pharmaceuticals Intl Inc (VRX) Stock With Reason | InvestorPlace

2017-10-05 investorplace
No doubt Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is still considered junk by some investors. Yet some might contend the price chart of VRX stock points to the possibility of shares being “head and shoulders” above many others. Let me explain. (164-0)

Stock Research Report

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products.

  • The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...
Click for full article
CUSIP: 91911K102